Figure 3 | Scientific Reports

Figure 3

From: PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Figure 3

Intrinsic overexpression of MDR1 and BCL2 genes associated with drug-resistance on MDR ovarian cancer cells. The amounts of MDR1 (A) and BCL2 mRNA (B) on SKOV3 or A2780 parent and resistant cells were measured without or in response to chemotherapeutics treatment. 0.1 μM and 1.8 μM of paclitaxel (PTX) were treated to SKOV3 and SKOV3-TR cells, respectively, and 0.04 μM and 28 μM of cisplatin (CP) were treated to A2780 and A2780-CP20 cells, respectively. qRT-PCR was performed to quantitatively determine the amounts of each mRNA. The results are represented as the mean ± s.d. (n = 3). The differences between intrinsic and induced expression levels in MDR1 or BCL2 genes on both cell lines were estimated as statistically nonsignificant under p < 0.05.

Back to article page